https://www.yiliao.com/index.php?action=history&feed=atom&title=Vepdegestrant
Vepdegestrant - 版本历史
2026-04-10T19:28:38Z
本wiki的该页面的版本历史
MediaWiki 1.35.1
https://www.yiliao.com/index.php?title=Vepdegestrant&diff=317415&oldid=prev
223.160.136.180：建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面
2026-03-23T07:18:11Z
<p>建立内容为“<div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff…”的新页面</p>
<p><b>新页面</b></p><div><div style="padding: 0 4%; line-height: 1.8; color: #1e293b; font-family: 'Helvetica Neue', Helvetica, 'PingFang SC', Arial, sans-serif; background-color: #ffffff; max-width: 1200px; margin: auto;"><br />
<br />
<div style="margin-bottom: 30px; border-bottom: 1.2px solid #e2e8f0; padding-bottom: 25px;"><br />
<p style="font-size: 1.1em; margin: 10px 0; color: #334155; text-align: justify;"><br />
<strong>[[Vepdegestrant]]</strong>，研发代码为<strong>[[ARV-471]]</strong>，是由Arvinas与[[辉瑞]]([[Pfizer]])联合开发的一种口服、高选择性的<strong>[[PROTAC]]（蛋白降解靶向联合体）</strong>。作为一种新型的<strong>[[雌激素受体]]([[ER]])降解剂</strong>，Vepdegestrant通过招募E3泛素连接酶，利用细胞自身的蛋白酶体系统诱导ER蛋白的泛素化与降解。与传统的[[SERM]]（如他莫昔芬）或[[SERD]]（如氟维司群）不同，Vepdegestrant能更彻底地清除靶蛋白，尤其是在处理含有<strong>[[ESR1突变]]</strong>的耐药性<strong>[[ER阳性/HER2阴性乳腺癌]]</strong>中展现出卓越的临床潜力。<br />
</p><br />
</div><br />
<br />
<div class="medical-infobox mw-collapsible" style="width: 320px; margin: 0 auto 35px auto; border: 1.2px solid #bae6fd; border-radius: 12px; background-color: #ffffff; box-shadow: 0 8px 20px rgba(0,0,0,0.05); overflow: hidden;"><br />
<br />
<div style="padding: 15px; color: #1e40af; background: linear-gradient(135deg, #f0f9ff 0%, #bae6fd 100%); text-align: center; cursor: pointer;"><br />
<div style="font-size: 1.2em; font-weight: bold; letter-spacing: 1.2px;">Vepdegestrant (ARV-471)</div><br />
<div style="font-size: 0.7em; opacity: 0.85; margin-top: 4px; white-space: nowrap;">ER PROTAC Degrader · 核心参数</div><br />
</div><br />
<br />
<div class="mw-collapsible-content"><br />
<div style="padding: 25px; text-align: center; background-color: #f8fafc;"><br />
<div style="display: inline-block; background: #ffffff; border: 1px solid #e2e8f0; border-radius: 12px; padding: 15px; box-shadow: 0 4px 10px rgba(0,0,0,0.04);"><br />
<div style="width: 140px; height: 90px; background-color: #f1f5f9; display: flex; align-items: center; justify-content: center; color: #94a3b8; font-size: 0.8em; padding: 10px; text-align: center; border-radius: 8px;">Mechanism: Targeted Estrogen Receptor Degradation via PROTAC</div><br />
</div><br />
<div style="font-size: 0.8em; color: #64748b; margin-top: 12px; font-weight: 600;">核心靶点：[[ER]] ([[ESR1]])</div><br />
</div><br />
<br />
<table style="width: 100%; border-spacing: 0; border-collapse: collapse; font-size: 0.85em;"><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0; width: 45%;">[[Entrez]] ID</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2099</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[HGNC]] 符号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">ESR1</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">[[UniProt]]</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">P03372</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">CAS号</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">2244837-41-4</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569; border-bottom: 1px solid #e2e8f0;">药物类型</th><br />
<td style="padding: 8px 12px; border-bottom: 1px solid #e2e8f0; color: #0f172a;">口服 PROTAC</td><br />
</tr><br />
<tr><br />
<th style="text-align: left; padding: 8px 12px; background-color: #f1f5f9; color: #475569;">开发阶段</th><br />
<td style="padding: 8px 12px; color: #1e40af; font-weight: bold;">临床 III 期 (VERITAC-2)</td><br />
</tr><br />
</table><br />
</div><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">分子机制：蛋白降解的革新</h2><br />
<br />
<p style="margin: 15px 0; text-align: justify;"><br />
Vepdegestrant的设计采用了经典的[[PROTAC]]双功能分子结构，一端结合雌激素受体（ER），另一端结合[[VHL]] E3泛素连接酶：<br />
</p><br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>三元复合物形成：</strong> 药物作为“桥梁”促成ER蛋白与E3连接酶的物理接触。</li><br />
<li style="margin-bottom: 12px;"><strong>蛋白酶体途径：</strong> E3连接酶催化ER蛋白的泛素化，随后该受体被输送至[[蛋白酶体]]进行降解。</li><br />
<li style="margin-bottom: 12px;"><strong>高效循环：</strong> 一分子Vepdegestrant可以催化多个ER分子的降解，具有催化活性，这使其在较低浓度下即可实现比竞争性抑制剂更彻底的受体阻断。</li><br />
<li style="margin-bottom: 12px;"><strong>针对ESR1突变：</strong> 临床前数据显示，Vepdegestrant对包括Y537S和D538G在内的常见[[ESR1]]抗性突变体具有强劲的降解能力。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">核心临床研究概览</h2><br />
<div style="overflow-x: auto; margin: 30px auto; width: 95%;"><br />
<table style="width: 100%; border-collapse: collapse; border: 1.2px solid #cbd5e1; font-size: 0.9em; text-align: left;"><br />
<tr style="background-color: #f8fafc; border-bottom: 2px solid #0f172a;"><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #0f172a; width: 25%;">研究名称</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #475569;">研究设计/人群</th><br />
<th style="padding: 12px; border: 1px solid #cbd5e1; color: #1e40af;">关键发现/地位</th><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[VERITAC]] (Ph 1/2)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">重度经治的ER+/HER2-晚期乳腺癌。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">在ESR1突变患者中临床获益率（CBR）显著，耐受性良好。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[VERITAC-2]] (Ph 3)</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">对比氟维司群，用于内分泌治疗后的晚期患者。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">旨在确立其作为新一代标准内分泌治疗（ET）的地位。</td><br />
</tr><br />
<tr><br />
<td style="padding: 10px; border: 1px solid #cbd5e1; font-weight: 600;">[[联合方案探索]]</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">联合[[哌柏西利]](CDK4/6i)或新型靶向药。</td><br />
<td style="padding: 10px; border: 1px solid #cbd5e1;">探索在一线或二线治疗中强化ER通路阻断的可能性。</td><br />
</tr><br />
</table><br />
</div><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">临床意义与应用挑战</h2><br />
<br />
<ul style="padding-left: 25px; color: #334155;"><br />
<li style="margin-bottom: 12px;"><strong>克服内分泌耐药：</strong> Vepdegestrant为CDK4/6抑制剂和芳香化酶抑制剂（AI）耐药后的患者提供了关键的后续选择。</li><br />
<li style="margin-bottom: 12px;"><strong>口服便利性：</strong> 相比需要每月肌肉注射的氟维司群，口服给药极大提升了患者的依从性和生活质量。</li><br />
<li style="margin-bottom: 12px;"><strong>安全性关注：</strong> 临床观察到的主要不良反应包括疲劳、恶心和关节痛，整体安全性谱系与传统内分泌药物相似，但需关注PROTAC类药物特有的长效代谢特征。</li><br />
</ul><br />
<br />
<h2 style="background: #f1f5f9; color: #0f172a; padding: 10px 18px; border-radius: 0 6px 6px 0; font-size: 1.25em; margin-top: 40px; border-left: 6px solid #0f172a; font-weight: bold;">关键相关概念</h2><br />
<div style="background-color: #f8fafc; border: 1px solid #e2e8f0; border-radius: 8px; padding: 15px; margin: 20px 0;"><br />
<ul style="margin: 0; padding-left: 20px; color: #334155; columns: 2;"><br />
<li style="margin-bottom: 8px;">[[PROTAC]]</li><br />
<li style="margin-bottom: 8px;">[[ESR1突变]]</li><br />
<li style="margin-bottom: 8px;">[[口服SERD]] ([[Elacestrant]])</li><br />
<li style="margin-bottom: 8px;">[[蛋白酶体降解]]</li><br />
<li style="margin-bottom: 8px;">[[VHL E3连接酶]]</li><br />
<li style="margin-bottom: 8px;">[[内分泌耐药]]</li><br />
</ul><br />
</div><br />
<br />
<div style="font-size: 0.92em; line-height: 1.6; color: #1e293b; margin-top: 50px; border-top: 2.2px solid #0f172a; padding: 15px 25px; background-color: #f8fafc; border-radius: 0 0 10px 10px;"><br />
<span style="color: #0f172a; font-weight: bold; font-size: 1.05em; display: inline-block; margin-bottom: 15px;">学术参考文献与权威点评</span><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[1] <strong>Snyder LB, et al. (2021).</strong> <em>The discovery of ARV-471, a potent and orally bioavailable PROTAC degrader of ER.</em> <strong>[[AACR Annual Meeting]]</strong>.<br><br />
<span style="color: #475569;">[学术点评]：该报告首次揭示了ARV-471在临床前模型中优于氟维司群的降解活性，开启了PROTAC在乳腺癌领域的应用。</span><br />
</p><br />
<br />
<p style="margin: 12px 0; border-bottom: 1px solid #e2e8f0; padding-bottom: 10px;"><br />
[2] <strong>Schott AF, et al. (2022).</strong> <em>ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/HER2- metastatic breast cancer.</em> <strong>[[SABCS]]</strong>. [Academic Review]<br><br />
<span style="color: #475569;">[权威点评]：VERITAC研究的数据确立了Vepdegestrant在ESR1突变型晚期乳腺癌中的治疗潜力。</span><br />
</p><br />
</div><br />
<br />
<div style="margin: 40px 0; border: 1px solid #e2e8f0; border-radius: 8px; overflow: hidden; font-size: 0.9em;"><br />
<div style="background-color: #eff6ff; color: #1e40af; padding: 8px 15px; font-weight: bold; text-align: center; border-bottom: 1px solid #dbeafe;"><br />
Vepdegestrant (ARV-471) 诊疗生态 · 知识图谱<br />
</div><br />
<table style="width: 100%; border-collapse: collapse; background-color: #ffffff;"><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">关联靶点</td><br />
<td style="padding: 10px 15px; color: #334155;">[[ESR1]]•[[VHL]]•[[ERα]]•[[蛋白酶体]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">同类/联用</td><br />
<td style="padding: 10px 15px; color: #334155;">[[氟维司群]]•[[Elacestrant]]•[[哌柏西利]]•[[阿贝西利]]</td><br />
</tr><br />
<tr style="border-bottom: 1px solid #f1f5f9;"><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">战略实体</td><br />
<td style="padding: 10px 15px; color: #334155;">[[Arvinas]]•[[Pfizer]]•[[FDA]]•[[NMPA]]</td><br />
</tr><br />
<tr><br />
<td style="width: 90px; background-color: #f8fafc; color: #334155; font-weight: 600; padding: 10px 12px; text-align: right; vertical-align: middle;">研究前沿</td><br />
<td style="padding: 10px 15px; color: #334155;">[[克服ESR1突变耐药]]•[[PROTAC催化效率量化]]•[[一线内分泌强化]]•[[生物标志物筛选]]</td><br />
</tr><br />
</table><br />
</div><br />
<br />
</div></div>
223.160.136.180